RxDoctor Payments Data

Julio Castro Quero, MD

Internal Medicine · Lafayette, LANPI 1972695724

Payments from drug & device makers

$1,562in general payments, 2019–2025

Across 78 payments — averaging $20.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$558
  • Novartis$209
  • Pfizer$192
  • Inari Medical, Inc.$180
  • AstraZeneca$124
  • E.r. Squibb & Sons, L.L.C.$105
  • plus $194 from 6 others

What the payments were for

  • Food & beverage$1,49496%
  • Education$684%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,562 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$117,821
Medicare patients
336
Services billed
988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban35$16,230
XareltoRivaroxaban12$10,766
EntrestoSacubitril/Valsartan19$9,432
Pantoprazole Sodium72$755
Levetiracetam31$628
Amiodarone Hcl26$358
Potassium Chloride24$343
Amlodipine Besylate62$335
Atorvastatin Calcium30$288
Carvedilol28$204
Metoprolol Succinate17$203
Diltiazem 24hr Er (Cd)Diltiazem Hcl13$200
ClopidogrelClopidogrel Bisulfate25$174
Furosemide50$150
Hydralazine Hcl12$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$192$16,23035 claims
Johnson & JohnsonXarelto$558$10,76612 claims
NovartisEntresto$209$9,43219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Lafayette

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →